Tianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025

Reuters

2025/09/05

Tianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025

Tianjin TEDA Biomedical Engineering Co. Ltd. reported its unaudited half-yearly results for the six months ended June 30, 2025. The company achieved a consolidated turnover of RMB226.4 million, marking a 7.01% increase from the RMB211.6 million recorded during the same period in 2024. The consolidated gross profit for the period was RMB13.8 million, up by 14.07% compared to RMB12.1 million in the previous year. However, the company reported a loss attributable to equity owners amounting to RMB6.4 million, which is a larger loss compared to the RMB4.1 million recorded in the corresponding period of 2024. The company did not recommend the payment of dividends for the six months ending June 30, 2025. Tianjin TEDA is primarily engaged in the biological compound fertilizer business, focusing on products that support the balanced growth of grains, fruit, and vegetables.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin TEDA Biomedical Engineering Co. Ltd. published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2565715554"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565715554\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565715554?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565715554","market":"fut","top_or_hot":-1,"title":"Tianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tianjin TEDA Biomedical Engineering Co. Ltd. reported its unaudited half-yearly results for the six months ended June 30, 2025. The company achieved a consolidated turnover of RMB226.4 million, marking a 7.01% increase from the RMB211.6 million recorded during the same period in 2024. The consolidated gross profit for the period was RMB13.8 million, up by 14.07% compared to RMB12.1 million in the previous year. However, the company reported a loss attributable to equity owners amounting to RMB6.4 million, which is a larger loss compared to the RMB4.1 million recorded in the corresponding period of 2024. The company did not recommend the payment of dividends for the six months ending June 30, 2025. Tianjin TEDA is primarily engaged in the biological compound fertilizer business, focusing on products that support the balanced growth of grains, fruit, and vegetables.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin TEDA Biomedical Engineering Co. Ltd. published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-05 18:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tianjin TEDA Biomedical Engineering Co. Ltd. reported its unaudited half-yearly results for the six months ended June 30, 2025. The company achieved a consolidated turnover of RMB226.4 million, marking a 7.01% increase from the RMB211.6 million recorded during the same period in 2024. The consolidated gross profit for the period was RMB13.8 million, up by 14.07% compared to RMB12.1 million in the previous year. However, the company reported a loss attributable to equity owners amounting to RMB6.4 million, which is a larger loss compared to the RMB4.1 million recorded in the corresponding period of 2024. The company did not recommend the payment of dividends for the six months ending June 30, 2025. Tianjin TEDA is primarily engaged in the biological compound fertilizer business, focusing on products that support the balanced growth of grains, fruit, and vegetables.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin TEDA Biomedical Engineering Co. Ltd. published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0250","symbol_name":"批發","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL551jfl:1","article_id":"2565715554","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565715554","pubTimestamp":1757069212,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tianjin TEDA Biomedical Engineering Co. Ltd. reported its unaudited half-yearly results for the six months ended June 30, 2025. The company achieved a consolidated turnover of RMB226.4 million, marking a 7.01% increase from the RMB211.6 million recorded during the same period in 2024. The consolidated gross profit for the period was RMB13.8 million, up by 14.07% compared to RMB12.1 million in the previous year. However, the company reported a loss attributable to equity owners amounting to RMB6.4 million, which is a larger loss compared to the RMB4.1 million recorded in the corresponding period of 2024. The company did not recommend the payment of dividends for the six months ending June 30, 2025. Tianjin TEDA is primarily engaged in the biological compound fertilizer business, focusing on products that support the balanced growth of grains, fruit, and vegetables.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0250":"批发","BK0116":"体育","BK0074":"参股金融","BK0028":"国家队","BK0013":"天津自贸区","BK0009":"债转股","000652":"泰达股份","08189":"泰达生物","BK1113":"化肥与农用药剂"},"translate_title":"天津泰达生物医药报告综合营业额增长7.01%，2025年上半年录得亏损人民币6.4百万元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"08189":0.9,"000652":0.9},"content_text":"Tianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025\n    \n\n        Tianjin TEDA Biomedical Engineering Co. Ltd. reported its unaudited half-yearly results for the six months ended June 30, 2025. The company achieved a consolidated turnover of RMB226.4 million, marking a 7.01% increase from the RMB211.6 million recorded during the same period in 2024. The consolidated gross profit for the period was RMB13.8 million, up by 14.07% compared to RMB12.1 million in the previous year. However, the company reported a loss attributable to equity owners amounting to RMB6.4 million, which is a larger loss compared to the RMB4.1 million recorded in the corresponding period of 2024. The company did not recommend the payment of dividends for the six months ending June 30, 2025. Tianjin TEDA is primarily engaged in the biological compound fertilizer business, focusing on products that support the balanced growth of grains, fruit, and vegetables.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin TEDA Biomedical Engineering Co. Ltd. published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}